Doxorubicin induces an alarmin-like TLR4-dependent autocrine/paracrine action of Nucleophosmin in human cardiac mesenchymal progenitor cells.


Journal

BMC biology
ISSN: 1741-7007
Titre abrégé: BMC Biol
Pays: England
ID NLM: 101190720

Informations de publication

Date de publication:
16 06 2021
Historique:
received: 28 07 2020
accepted: 28 05 2021
entrez: 17 6 2021
pubmed: 18 6 2021
medline: 2 2 2022
Statut: epublish

Résumé

Doxorubicin (Dox) is an anti-cancer anthracycline drug that causes double-stranded DNA breaks. It is highly effective against several types of tumours; however, it also has adverse effects on regenerative populations of normal cells, such as human cardiac mesenchymal progenitor cells (hCmPCs), and its clinical use is limited by cardiotoxicity. Another known effect of Dox is nucleolar disruption, which triggers the ubiquitously expressed nucleolar phosphoprotein Nucleophosmin (NPM) to be released from the nucleolus into the cell, where it participates in the orchestration of cellular stress responses. NPM has also been observed in the extracellular space in response to different stress stimuli; however, the mechanism behind this and its functional implications are as yet largely unexplored. The aim of this study was to establish whether Dox could elicit NPM secretion in the extracellular space and to elucidate the mechanism of secretion and the effect of extracellular NPM on hCmPCs. We found that following the double-strand break formation in hCmPCs caused by Dox, NPM was rapidly secreted in the extracellular space by an active mechanism, in the absence of either apoptosis or necrosis. Extracellular release of NPM was similarly seen in response to ultraviolet radiation (UV). Furthermore, we observed an increase of NPM levels in the plasma of Dox-treated mice; thus, NPM release also occurred in vivo. The treatment of hCmPCs with extracellular recombinant NPM induced a decrease of cell proliferation and a response mediated through the Toll-like receptor (TLR)4. We demonstrated that NPM binds to TLR4, and via TLR4, and nuclear factor kappa B (NFkB) activation/nuclear translocation, exerts proinflammatory functions by inducing IL-6 and COX-2 gene expression. Finally, we found that in hCmPCs, NPM secretion could be driven by an autophagy-dependent unconventional mechanism that requires TLR4, since TLR4 inhibition dramatically reduced Dox-induced secretion. We hypothesise that the extracellular release of NPM could be a general response to DNA damage since it can be elicited by either a chemical agent such as Dox or a physical genotoxic stressor such as UV radiation. Following genotoxic stress, NPM acts similarly to an alarmin in hCmPCs, being rapidly secreted and promoting cell cycle arrest and a TLR4/NFκB-dependent inflammatory response.

Sections du résumé

BACKGROUND
Doxorubicin (Dox) is an anti-cancer anthracycline drug that causes double-stranded DNA breaks. It is highly effective against several types of tumours; however, it also has adverse effects on regenerative populations of normal cells, such as human cardiac mesenchymal progenitor cells (hCmPCs), and its clinical use is limited by cardiotoxicity. Another known effect of Dox is nucleolar disruption, which triggers the ubiquitously expressed nucleolar phosphoprotein Nucleophosmin (NPM) to be released from the nucleolus into the cell, where it participates in the orchestration of cellular stress responses. NPM has also been observed in the extracellular space in response to different stress stimuli; however, the mechanism behind this and its functional implications are as yet largely unexplored. The aim of this study was to establish whether Dox could elicit NPM secretion in the extracellular space and to elucidate the mechanism of secretion and the effect of extracellular NPM on hCmPCs.
RESULTS
We found that following the double-strand break formation in hCmPCs caused by Dox, NPM was rapidly secreted in the extracellular space by an active mechanism, in the absence of either apoptosis or necrosis. Extracellular release of NPM was similarly seen in response to ultraviolet radiation (UV). Furthermore, we observed an increase of NPM levels in the plasma of Dox-treated mice; thus, NPM release also occurred in vivo. The treatment of hCmPCs with extracellular recombinant NPM induced a decrease of cell proliferation and a response mediated through the Toll-like receptor (TLR)4. We demonstrated that NPM binds to TLR4, and via TLR4, and nuclear factor kappa B (NFkB) activation/nuclear translocation, exerts proinflammatory functions by inducing IL-6 and COX-2 gene expression. Finally, we found that in hCmPCs, NPM secretion could be driven by an autophagy-dependent unconventional mechanism that requires TLR4, since TLR4 inhibition dramatically reduced Dox-induced secretion.
CONCLUSIONS
We hypothesise that the extracellular release of NPM could be a general response to DNA damage since it can be elicited by either a chemical agent such as Dox or a physical genotoxic stressor such as UV radiation. Following genotoxic stress, NPM acts similarly to an alarmin in hCmPCs, being rapidly secreted and promoting cell cycle arrest and a TLR4/NFκB-dependent inflammatory response.

Identifiants

pubmed: 34134693
doi: 10.1186/s12915-021-01058-5
pii: 10.1186/s12915-021-01058-5
pmc: PMC8210386
doi:

Substances chimiques

Alarmins 0
NF-kappa B 0
Nuclear Proteins 0
TLR4 protein, human 0
Tlr4 protein, mouse 0
Toll-Like Receptor 4 0
Nucleophosmin 117896-08-9
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

124

Subventions

Organisme : Marie Curie
ID : FP7-PEOPLE-2011-CIG-294176
Pays : United Kingdom
Organisme : Ministero della Salute
ID : RF-02362708
Organisme : Ministero della Salute
ID : RF-02362708
Organisme : Ministero della Salute
ID : SG-12358253
Organisme : Ministero della Salute
ID : RC2015/16
Organisme : AFM-Téléthon
ID : 22522
Organisme : Idi Farmaceutici s.r.l.
ID : IDIFAR18MG
Organisme : NIH HHS
ID : Intramural Research
Pays : United States
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : AIRCIG2011-ID11793

Références

J Biol Chem. 2006 Jun 16;281(24):16536-45
pubmed: 16608843
J Clin Invest. 2001 Jan;107(1):13-9
pubmed: 11134172
Nat Methods. 2006 Dec;3(12):995-1000
pubmed: 17072308
Pharmacol Rep. 2009 Jan-Feb;61(1):154-71
pubmed: 19307704
Int J Mol Sci. 2012 Dec 21;14(1):205-25
pubmed: 23344029
Cardiovasc Res. 2011 Feb 1;89(2):362-73
pubmed: 20833650
Circulation. 2010 Jan 19;121(2):276-92
pubmed: 20038740
Cancer Res. 2008 Mar 1;68(5):1398-406
pubmed: 18316603
J Mol Cell Cardiol. 2006 Sep;41(3):389-405
pubmed: 16879835
Nat Cell Biol. 2002 Jul;4(7):529-33
pubmed: 12080348
Nucleic Acids Res. 2010 Nov;38(20):7248-59
pubmed: 20615901
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731):
pubmed: 28847817
Nucleic Acids Res. 2011 Sep 1;39(16):7223-33
pubmed: 21609964
Cell Death Dis. 2017 Aug 24;8(8):e3020
pubmed: 28837147
FEBS Lett. 2001 Oct 12;506(3):272-6
pubmed: 11602260
Open Life Sci. 2018 Aug 21;13:236-241
pubmed: 33817088
Genomics Proteomics Bioinformatics. 2016 Jun;14(3):147-154
pubmed: 27221660
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6145-50
pubmed: 21444791
J Leukoc Biol. 2009 Sep;86(3):645-53
pubmed: 19581374
Front Physiol. 2017 Jul 19;8:508
pubmed: 28769820
J Biol Chem. 2009 Jun 12;284(24):16409-16418
pubmed: 19366707
Biochemistry. 1997 Apr 1;36(13):3941-9
pubmed: 9092824
Cytokine. 2008 May;42(2):145-151
pubmed: 18304834
Cancer Res. 2016 Nov 15;76(22):6631-6642
pubmed: 27680684
Nucleic Acids Res. 2017 Apr 20;45(7):3707-3723
pubmed: 28003476
Autophagy. 2021 Feb;17(2):529-552
pubmed: 32019420
Biochem Pharmacol. 2015 Nov 1;98(1):132-43
pubmed: 26367307
Cardiovasc Res. 2011 Feb 15;89(3):650-60
pubmed: 20833652
EMBO J. 2003 Nov 17;22(22):6068-77
pubmed: 14609953
Eur J Heart Fail. 2008 Mar;10(3):233-43
pubmed: 18321777
Oncogene. 2008 Sep 25;27(43):5696-705
pubmed: 18542057
BMC Cardiovasc Disord. 2011 Oct 14;11:62
pubmed: 21999911
J Am Soc Echocardiogr. 2014 May;27(5):568-79
pubmed: 24534652
Biomed Rep. 2021 Feb;14(2):21
pubmed: 33335727
Mol Cell Biol. 2008 Jan;28(2):873-82
pubmed: 17991896
Cell. 1989 Feb 10;56(3):379-90
pubmed: 2914325
J Clin Oncol. 2010 Sep 1;28(25):3910-6
pubmed: 20679614
Protein Sci. 1999 Apr;8(4):905-12
pubmed: 10211837

Auteurs

Sara Beji (S)

Experimental Immunology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via Monti di Creta 104, 00167, Rome, Italy.

Marco D'Agostino (M)

Experimental Immunology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via Monti di Creta 104, 00167, Rome, Italy.

Elisa Gambini (E)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino, IRCCS, Via Carlo Parea 4, 20138, Milan, Italy.

Sara Sileno (S)

Experimental Immunology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via Monti di Creta 104, 00167, Rome, Italy.

Alessandro Scopece (A)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino, IRCCS, Via Carlo Parea 4, 20138, Milan, Italy.

Maria Cristina Vinci (MC)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino, IRCCS, Via Carlo Parea 4, 20138, Milan, Italy.

Giuseppina Milano (G)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino, IRCCS, Via Carlo Parea 4, 20138, Milan, Italy.

Guido Melillo (G)

Unit of Cardiology, IDI-IRCCS, Rome, Italy.

Monica Napolitano (M)

Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.

Giulio Pompilio (G)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino, IRCCS, Via Carlo Parea 4, 20138, Milan, Italy.
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

Maurizio C Capogrossi (MC)

Laboratory of Cardiovascular Science, National Institute on Aging (NIA), National Institutes of Health (NIH), 251 Bayview Blvd, Baltimore, MD, 21224, USA.
Division of Cardiology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

Daniele Avitabile (D)

Idi Farmaceutici S.r.l., Via dei Castelli Romani 83/85, 00071, Pomezia (Rome), Italy. davitabile@idifarmaceutici.it.

Alessandra Magenta (A)

National Research Council of Italy (CNR), Institute of Translational Pharmacology IFT, Via Fosso del Cavaliere 100, 00133, Rome, Italy. ale.magenta@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH